Revenue rose 27% year-over-year to $23.3 million in Q2 2026, with strong U.S. and BioPharma growth. Adjusted EBITDA loss improved 27%, and 2026 revenue guidance was raised to $94–96 million. Major new partnerships and a $57.5 million capital raise support future growth.Original document: SOPHiA GEN…
Revenue rose 27% year-over-year to $23.3 million in Q2 2026, with strong U.S. and BioPharma growth. Adjusted EBITDA loss improved 27%, and 2026 revenue guidance was raised to $94–96 million. Major new partnerships and a $57.5 million capital raise support future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
